Novopyxis is structured around development of therapeutics and medical devices. The firm's flagship drug was developed using in-house proprietary mathematical algorithms and has been validated across several different in vitro, ex vivo and in vivo models. Recently awarded by the FDA orphan designation for "Pediatric Cardiomyopathy", the drug serves to activates a key anti-inflammatory receptor called the AT2R and is both cardioprotective and neuroprotective. The firm's therapeutic designated Droplette was recently spun out from Novopyxis (www.droplette.io) and is focused on development of a patented medical device for delivery of large molecules, DNA/RNA, and proteins deep through skin, tissue, and cells.
